RxDoctor Payments Data

Sandeep Chowdhary, MD

Pulmonary Disease · West Jordan, UTNPI 1891726162

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.

$6,593in general payments, 2019–2025

Across 373 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$735
  • GSK$522
  • Boehringer Ingelheim$504
  • United Therapeutics Corporation$455
  • Mylan Specialty L.p.$405
  • Harmony Biosciences LLC$398
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$6,46398%
  • Education$1302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,593 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$120,540
Medicare patients
405
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$234,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$55,372
Spiriva RespimatTiotropium Bromide40$27,989
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$13,316
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$10,387
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,778
SymbicortBudesonide/Formoterol Fumarate16$5,528
Breo ElliptaFluticasone/Vilanterol13$4,535
Albuterol Sulfate HfaAlbuterol Sulfate44$1,478
Fluticasone Propionate47$650
Omeprazole35$503
Montelukast Sodium53$494
Azithromycin44$289
Famotidine15$132
Prednisone20$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$204$234,94413 claims
GSKTrelegy Ellipta, Breo Ellipta$522$59,90878 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$504$41,30452 claims
AstraZenecaBreztri Aerosphere, Symbicort$735$15,30731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Utah.

Other pulmonary disease in West Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →